Ironwood Pharmaceuticals (IRWD) Operating Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Operating Expenses across 17 years of filings, most recently posting $33.9 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $33.9 million, down 51.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.3 million (down 39.05% YoY), and the FY2025 annual result was $197.6 million, down 23.48% from the prior year.
• Operating Expenses came in at $33.9 million for Q1 2026 at Ironwood Pharmaceuticals, down from $40.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.2 billion in Q2 2023 to a low of $33.9 million in Q1 2026.
• The 5-year median for Operating Expenses is $46.6 million (2025), against an average of $119.9 million.
• Across the five-year window, Operating Expenses soared 2763.48% in 2023 and tumbled 94.17% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Operating Expenses stood at $38.8 million in 2022, then soared by 105.9% to $80.0 million in 2023, then decreased by 26.15% to $59.1 million in 2024, then tumbled by 30.73% to $40.9 million in 2025, then declined by 17.04% to $33.9 million in 2026.
• The last three Operating Expenses figures came in at $33.9 million (Q1 2026), $40.9 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.